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Abstract
Leser-Trélat syndrome is characterized by the eruptive appearance of multiple seborrheic keratoses in association
with underlying malignant disease. Usually, the sign of Leser-Trélat is associated with adenocarcinoma, most fre-
quently of the colon, breast, or stomach, but also of the lung, kidney, liver, and pancreas. Herein, we present a case
that we believe is the first report of the sign of Leser-Trélat in association with occult gastric adenocarcinoma and
the anamnestic oncologic history of five other multiple primitive cancers. Epidermal growth factor receptor (EGFR)
immunohistochemical expression analysis of multiple seborrheic keratoses revealed an intense membranous stain-
ing in the basal keratinocytes and in all the upper epidermal layers. Patients with the sign of Leser-Trélat should
undergo a diagnostic screening programme for malignant disease along with patients with known Leser-Trélat
syndrome who present with a recent acute and florid eruption of their seborrheic keratoses. We propose the
importance of combining the molecular features of multiple seborrheic keratoses with EGFR immunohistochemistry
analyses to determine the likelihood of Leser-Trélat syndrome and the consequent high risk of underlying multiple
visceral malignancies.
Background
Skin manifestations are frequently observed in many
internal malignancies. Cutaneous lesions, including
benign neoplasms or pigmented lesions, can appear in
the context of specific genodermatosis [1,2], lentiginosis
[3], or paraneoplastic syndrome [4] representing a cru-
cial cutaneous marker of internal malignancy in both
the sporadic and genetic setting. Several familial cancer
syndromes have additional malignant or non-malignant
cutaneous features that form part of the clinical diag-
nostic criteria constituting a critical tool for clinical
diagnosis.
Several cutaneous paraneoplastic syndromes may be
associated with underlying tumours. They include mus-
culoskeletal disorders (clubbing, hypertrophic osteoar-
thropathy, dermatomyositis, and multicentric
reticulohistiocytosis), reactive erythemas (erythema gyra-
tum repens and necrolytic migratory erythema), vascular
dermatoses (Trousseau’s syndrome), papulosquamous
disorders (acanthosis nigricans, tripe palms, palmar
hyperkeratosis, acquired ichthyosis, pityriasis rotunda,
Bazex’s syndrome, florid cutaneous papillomatosis and
extramammary Paget’s disease), and disorders of hair
growth (hypertrichosis lanuginosa acquisita) (Table 1)
[4]. The clinical manifestations of these dermatoses may
precede, coincide with, or follow the diagnosis of cancer.
Most paraneoplastic dermatoses disappear when the pri-
mary tumour is removed and reappear in the case of
recurrence or metastases of the cancer.
The sign of Leser-Trélat is characterized by the erup-
tive appearance of multiple seborrheic keratoses (SK) in
association with underlying malignant disease. Two Eur-
opean surgeons, Edmund Leser and Ulisse Trélat, were
the first to describe the sign, and although they gave no
mention of the presence of seborrheic keratoses report-
ing a specific association with angiomas - that probably
does not exist - their names continue to be linked to a
different paraneoplastic association [5]. In 1900, a subse-
quent report clearly defined the association of sebor-
rheic keratosis and cancer [6]. Usually, the sign of
Leser-Trélat is associated with adenocarcinoma, most
frequently of the colon, breast, or stomach, but also of
the kidney, liver, and pancreas, among others [7,8].
Endogenous mediators of hyperproliferative skin dis-
ease such as epidermal growth factor (EGF), transform-
ing growth factor-alpha (TGF-a), or amphiregulin that
may function in a localized autocrine manner or be
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diffusely, may induce some seborrheic keratoses [9,10].
H e r e i n ,w ep r e s e n tac a s et h a tw eb e l i e v ei st h ef i r s t
report of Leser-Trélat syndrome in association with
occult gastric adenocarcinoma and the anamnestic
oncologic history of five other multiple primitive
cancers.
Case presentation
A 83-year-old man was admitted to our hospital in
August 2009 with a recent history of dyspnea, cough
and dyspepsia. His medical history was characterized by
sigmoidectomy and ileal-cecal resection for two syn-
chronous adenocarcinomas (T1N0M0) in August 2008;
localized adenocarcinoma of the prostate diagnosed in
2007 treated with hormonotherapy and radiotherapy
with radical intent; cutaneous basal cell carcinoma and
squamous cell carcinoma removed about 10 years
before. For the past 25 years, he had noted multiple
asymptomatic lesions, diagnosed as multiple seborrheic
keratosis, of the face and trunk and these had recently
increased in size and number with generalized pruritis.
On admission, dermatologic examination noted florid
eruption of innumerable keratotic lesions of the face,
neck and thorax, ranging in size from 3 to 15 mm (Fig-
ure 1). Histopathological examination of a surgical skin
biopsy confirmed the clinical diagnosis of seborrheic
keratosis and was used for EGFR immunohistochemical
analysis (Figure 2). Immunoperoxidase staining using
diaminobenzidine as chromogen was run with the
Benchmark XT automatic staining system (Ventana
Medical Systems Inc, Strasbourg, France). Mouse
monoclonal antibody anti-EGFR (clone 31G7; Ventana,
Strasbourg, France) was used at a dilution of 1:100.
In July 2009, computed tomography (CT) of the chest
and abdomen revealed a 2.5 by 2.0-cm solid mass in the
upper lobe of his right lung. Diagnosis of gastric adeno-
carcinoma was obtained at histological analysis by lung
biopsy which revealed signet ring cells, and at clinical
evaluation of his gastric symptoms (gastric pain, dyspep-
sia). Contemporaneously, due to haematologic pancyto-
penia, the patient was studied by bone marrow biopsy
(BOM) that revealed a diffuse infiltration of adenocarci-
noma with signet ring cells at histological analysis. The
patient died of disease progression in September 2009.
The patient’s sister had died of neck cancer at the age
of 50 years. There was no history of malignancies in the
patient’s mother, father or other first-degree relatives.
Discussion
The clinical association of florid eruption of seborrheic
keratoses and diagnosis of malignancy clearly identify
Leser-Trélat syndrome. Heaphy et al. [11] suggest that it
would be useful to distinguish between a “sign of Leser-
Trélat” and a “syndrome of Leser-Trélat.” They propose
that the “sign of Leser-Trélat” be defined as a sudden
acute efflorescence of seborrheic keratoses sometimes
accompanied by pruritus or acanthosis nigricans (or
both). According to this definition, the sign may be pre-
sent with or without occult malignancy and is detectable
on history and physical examination alone. The term
“syndrome of Leser-Trélat” would then be used to
d e s c r i b eap a r a n e o p l a s t i cs y n d r o m ei np a t i e n t sw i t ht h e
“sign of Leser-Trélat” in whom an occult malignancy
was identified after the appearance of the sign.
Table 1 Cutaneous manifestations of internal malignancies
Cutaneous feature Clinical findings Associated malignancy
Acanthosis nigricans
(malignant)
Velvety hyperpigmented thickening extending beyond the
flexures and neck to involve lips, palms
Intra-abdominal adenocarcinoma, lung
carcinoma, lymphoreticular malignancies
Acrokeratosis paraneoplastica
(Bazex’s syndrome)
Psoriasiform dermatitis with nail dystrophy affecting hands,
feet, ears, nose
Squamous cell carcinoma of upper aerodigestive
tract
Erythema gyratum repens Wood grain pattern annular, scaling erythema Lung carcinoma
Necrolytic migratory erythema Eroded erythematous annular polycyclic eruption affecting
intertriginous areas
Glucagonoma
Sweet syndrome Plum coloured nodules affecting head, neck and dorsae, hands Can be associated with leukaemia, lymphoma,
multiple myeloma
Pyoderma gangrenosum
especially bullous variant
Painful inflammatory ulcers with raised violaceous edge and
overhanging borders; associated pathergy
Can be associated with leukaemia, lymphoma,
multiple myeloma
Paraneoplastic pemphigus Bullous, erosive mucosal +/- cutaneous eruption Haematologic malignancies, thymoma
Necrobiotic xanthogranuloma Purpuric yellow plaques in periorbital and flexural areas Monoclonal gammopathy/multiple myeloma
Diffuse plane xanthomas Yellow-orange macules and plaques Monoclonal gammopathy/multiple myeloma
Scleromyxoedema Scleroderma-like thickening of skin associated with coloured
skin or erythematous papular infiltrate
Monoclonal gammopathy/multiple myeloma
Primary systemic amyloidosis Macroglossia, purpura especially periorbital and infiltrated
papules
Monoclonal gammopathy/multiple myeloma
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Page 2 of 5Figure 1 Clinical presentation of innumerable seborrheic keratoses concentrated over the face, neck, back, and chest.
Figure 2 (a) Histopathologic features and (b) immunohistochemical expression of EGFR in specimen from back lesion showing intense
membranous staining of EGFR in the basal keratinocytes and throughout the upper epidermal layer.
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the sign of Leser-Trélat is confirmed by the diagnosis of
anamnestic or recent malignancies, patients affected by
this syndromic disorder should be carefully monitored
for different visceral and potentially multiple primitive
malignancies. This instrumental surveillance strategy
should be tailored taking into account either the novel
sudden eruption of SK or the size and change in num-
ber of known SK. Regarding the type of associated
malignancies, the sign of Leser-Trélat is usually asso-
ciated with an adenocarcinoma, often in the stomach or
colon, although squamous cell carcinoma, lymphoma,
and leukaemias may also be observed. However, about
20% of patients reportedly have a lymphoma or a leu-
kaemia rather than an adenocarcinoma. The distribution
of the underlying cancer is similar to that of malignant
acanthosis nigricans, that is, adenocarcinomas predomi-
nate, especially in the stomach and the colon.
Seborrheic keratoses are exceedingly common and
various authors have doubted the existence of anything
other than a chance or coincidental association in the
sign of Leser-Trélat [11]. In other known cutaneous
paraneoplastic syndromes, the rarity of the skin manifes-
tation also permits a specific correlation to the origin of
the underlying malignancy (Table 1).
T h e r ei ss o m ee v i d e n c ef o rah u m o r a ll i n kb e t w e e n
various malignancies and the rapid onset of paraneo-
plastic syndrome. Ellis et al. [10] identified a role for
growth factors in the production of cutaneous paraneo-
plastic syndromes. Normally, epidermal growth factor
(EGF) receptors are present on basal keratinocytes and
decrease as the keratinocytes differentiate in the upper
epidermal layers. In the case presented, the immunohis-
tochemical analyses of EGFR protein revealed an intense
membranous staining in the basal keratinocytes and in
all the upper epidermal layers except the stratum cor-
neum; in addition, cytoplasmic positivity was revealed in
almost 50% of the cells (Figure 2). This is in accordance
with the data of Ellis et al. [10], in which biopsy speci-
mens of acanthosis nigricans, seborrheic keratoses, and
acrochordons showed intense staining for EGF receptors
in all epidermal layers, except the stratum corneum,
showing that EGFR overexpression may be one of the
concomitant pathognomonic mechanisms responsible
for sudden multiple eruption of SK.
Importantly, a question to consider is whether, given
the relative frequency of such lesions, routine immuno-
histochemical (IHC) testing may be warranted for any
multiple SK. We propose that EGFR immunohistochem-
ical analysis indicates the presence of LTS only when
some additional clinical information is present (sudden
multiple SK eruption, acute morphological changes of
chronic multiple SK, association with acanthosis nigri-
cans or other paraneoplastic skin manifestations, early
age at onset of SK, individual or familial history of
malignancies). In these settings, the SK sign should be
carefully examined through IHC tests even when they
appear in individuals without evidence of visceral malig-
nancy. Systematic analyses of EGFR IHC expression in
multiple SK of patients affected by LTS will provide
more information on the role of concomitant hormonal
alterations underlying multiple SK and visceral
cancerogenesis.
In the literature, only a few cases of LTS have been
reported [8,9,12]. In fact, although seborrheic keratoses
are common findings, the early appearance of these ker-
atoses and their eruptive nature are uncommon. How-
ever, we believe that LTS is underestimated probably
because of the lack of importance assigned to multiple
SK (mSK) in personal clinical surveys. As multiple SK
may be under- or misdiagnosed in common clinical
practice, we suggest that a proper dermatologic evalua-
tion should be conducted in all cases of sudden eruption
or intensification of chronic SK in order to fully evaluate
the frequency of this association.
Patients with sign of Leser-Trélat should undergo a
diagnostic screening programme for malignant disease
along with patients with known Leser-Trélat syndrome
who present with a recent acute and florid eruption of
their seborrheic keratoses. We propose the importance
of combining the molecular features of multiple sebor-
rheic keratoses with EGFR immunohistochemistry ana-
lyses to determine the likelihood of Leser-Trélat
syndrome and consequent high risk of visceral cancer
development.
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